Get the Stockscreener App
1.39
1.46%
0.02
After Hours:
1.35
-0.04
-2.88%
Telomir Pharmaceuticals Inc stock is traded at $1.39, with a volume of 150.30K.
It is up +1.46% in the last 24 hours and down -0.71% over the past month.
Telomir Pharmaceuticals Inc is a pioneering preclinical-stage pharmaceutical company which leads the advancement of age-reversal science. The Company is focused on developing Telomir-1, a novel small molecule designed to lengthen and protect telomeres-the protective DNA end caps of chromosomes that are crucial to cellular aging. As humans and animals age, telomeres naturally shorten, with metal reactivity accelerating this process, increasing the risk of degenerative and age-related diseases. By addressing the underlying causes of aging at the cellular level, Telomir aims to tackle the root of these conditions rather than simply treating their symptoms. Telomir is conducting ongoing preclinical research into Progeria, diabetes, cancer, Alzheimer's disease, osteoarthritis, and others.
See More
Previous Close:
$1.37
Open:
$1.36
24h Volume:
150.30K
Relative Volume:
0.25
Market Cap:
$47.79M
Revenue:
-
Net Income/Loss:
$-16.14M
P/E Ratio:
-2.5741
EPS:
-0.54
Net Cash Flow:
$-3.99M
1W Performance:
+2.21%
1M Performance:
-0.71%
6M Performance:
+20.87%
1Y Performance:
-70.98%
1-Day Range:
$1.355
$1.41
1-Week Range:
$1.32
$1.41
52-Week Range:
$1.12
$5.40
Telomir Pharmaceuticals Inc Stock (TELO) Company Profile
Name
Telomir Pharmaceuticals Inc
Sector
Industry
Phone
786-396-6723
Address
100 SE 2ND ST, MIAMI
Compare TELO with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
TELO
Telomir Pharmaceuticals Inc
|
1.39 | 47.10M | 0 | -16.14M | -3.99M | -0.54 |
|
VRTX
Vertex Pharmaceuticals Inc
|
441.36 | 111.36B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
733.04 | 77.98B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ARGX
Argen X Se Adr
|
800.01 | 50.33B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
359.27 | 47.46B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
338.19 | 37.43B | 4.98B | 69.59M | 525.67M | 0.5197 |
Telomir Pharmaceuticals Inc Stock (TELO) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Feb-21-25 | Initiated | Rodman & Renshaw | Buy |
Telomir Pharmaceuticals Inc Stock (TELO) Latest News
Financial Survey: Telomir Pharmaceuticals (NASDAQ:TELO) versus electroCore (NASDAQ:ECOR) - Defense World
Gainers Report: What are the risks of holding Telomir Pharmaceuticals Inc2025 Stock Rankings & Daily Stock Trend Reports - baoquankhu1.vn
Will Telomir Pharmaceuticals Inc outperform small cap indexesJuly 2025 Review & Low Risk Entry Point Tips - baoquankhu1.vn
Rodman & Renshaw initiates Telomir Pharma stock with Buy rating By Investing.com - Investing.com Canada
Aug Shorts: Is ImmuCell Corporation forming a bullish divergenceEarnings Overview Summary & Weekly Stock Breakout Alerts - baoquankhu1.vn
Telomir Pharmaceuticals Received Notice of Noncompliance - TradingView — Track All Markets
Is Telomir Pharmaceuticals Inc. stock a top momentum playJuly 2025 Summary & Growth Focused Entry Point Reports - Улправда
Published on: 2026-01-10 12:17:57 - Улправда
Telomir Pharmaceuticals Inc. (TELO) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade
Aug Movers: Why Telomir Pharmaceuticals Inc. stock is recommended by analystsGlobal Markets & Real-Time Market Trend Scan - Улправда
Is Telomir Pharmaceuticals Inc. stock in correction or buying zoneJuly 2025 Outlook & Advanced Swing Trade Entry Alerts - Улправда
Why retail investors favor Telomir Pharmaceuticals Inc. stockQuarterly Portfolio Summary & AI Forecast for Swing Trade Picks - Улправда
Trend Review: Why retail investors favor Telomir Pharmaceuticals Inc stockEarnings Growth Report & Step-by-Step Trade Execution Guides - Bộ Nội Vụ
Can Telomir Pharmaceuticals Inc. stock sustain revenue growthMerger & Acquisition Updates & Build Wealth With Expert Timing Advice - Улправда
Telomir Pharmaceuticals Announces Telomir-1 Significantly Reduced Tumor Growth and Metastases in Aggressive Triple-Negative Breast Cancer Animal Models - The Florida Times-Union
How Telomir Pharmaceuticals Inc. stock reacts to inflationary pressuresLow Risk Investment Ideas & Minimal Investment Portfolio Growth - ulpravda.ru
Telomir Pharmaceuticals reports preclinical results for Telomir-1 in TNBC models - Investing.com Australia
Coinbase CEO Brian Armstrong Says His Biotech Company Is Working On 'Extending' Human Lifespan: Here Is How They Plan To Do It - Benzinga
Telomir Highlights Positive Preclinical Results for Telomir-1 in TNBC - TipRanks
Telomir Pharmaceuticals Reports Positive Preclinical Results for Telomir-1 - TradingView — Track All Markets
Experimental breast cancer drug slows aggressive tumors in animal tests - Stock Titan
Is Telomir Pharmaceuticals Inc. stock positioned for digital transformationOptions Trading Strategies & Start Investing With Free Smart Watchlists - bollywoodhelpline.com
Telomir Pharmaceuticals reports preclinical results for Telomir-1 in TNBC models By Investing.com - Investing.com Nigeria
Telomir Pharmaceuticals Reports Favorable IND-Enabling GLP Safety Results for Telomir-1 Supporting First-in-Human Clinical Development - Lancaster Eagle-Gazette
Telomir Pharmaceuticals (NASDAQ:TELO) Shares Down 8.9% – Here’s What Happened - Defense World
Telomir Pharmaceuticals (NASDAQ:TELO) Shares Down 8.9%Here's What Happened - MarketBeat
Is Telomir Pharmaceuticals Inc stock oversold or undervaluedRisk Management & Weekly Hot Stock Watchlists - moha.gov.vn
Telomir Pharmaceuticals announces Telomir-1 reverses calcium dysregulation in multiple human cell lines - MSN
Momentum Shift: What is the fair value of Telomir Pharmaceuticals Inc stock nowPortfolio Profit Report & AI Driven Stock Movement Reports - Bộ Nội Vụ
Telomir Pharmaceuticals sets CEO incentive awards and salary adjustment - Investing.com
Telomir Pharmaceuticals Inc Stock (TELO) Financials Data
Revenue
Net Income
Cash Flow
EPS
4.73%
0.92%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):